Stakeholder analysis of tobacco control policy in Iran: a qualitative study

被引:0
作者
Arabloo, Jalal [1 ,2 ]
Ravaghi, Hamid [3 ]
Tourani, Sogand [3 ]
Kabiri, Neda [4 ,5 ]
Hajizadeh, Mohammad [6 ]
Khodayari-zarnaq, Rahim [7 ]
Pishgoo, Azita [8 ]
机构
[1] Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Publ Hlth, Tehran, Iran
[3] Iran Univ Med Sci, Sch Hlth Management & Informat Sci, Tehran, Iran
[4] Tabriz Univ Med Sci, Res Ctr Evidence Based Med, Tabriz, Iran
[5] Tabriz Univ Med Sci, Res Ctr Psychiat & Behav Sci, Tabriz, Iran
[6] Dalhousie Univ, Sch Hlth Adm, Halifax, NS, Canada
[7] Tabriz Univ Med Sci, Sch Management & Med Informat, Dept Hlth Policy & Management, Tabriz, Iran
[8] Shahid Beheshti Univ Med Sci, Sch Publ Hlth & Safety, Tehran, Iran
来源
DISCOVER SOCIAL SCIENCE AND HEALTH | 2025年 / 5卷 / 01期
关键词
Stakeholder analysis; Tobacco control; Health policy; Iran; INDUSTRY;
D O I
10.1007/s44155-025-00164-x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundTobacco control in low- and middle-income countries is a complex issue due to powerful economic and political bodies in the production and distribution of tobacco products. The urgent need for effective tobacco control measures is highlighted by the rising health burden associated with tobacco use in Iran, necessitating a comprehensive stakeholder analysis. The current study aimed to analyze the roles and characteristics of all stakeholders involved in tobacco control policymaking in Iran.MethodsAdhering to the theoretical framework introduced by Varvasovsky and Brugha, a qualitative stakeholder analysis was conducted based on five items of stakeholders' roles, interests, positions, powers and influences. The actors included in the study encompassed governmental bodies, non-governmental organizations (NGOs), the tobacco industry, health organizations, and the international community. The data were collected using semi-structured interviews with 36 key informants. MAXQDA V.10 software was used to analyze interviews by content analysis, and PolicyMaker software V.4 was used to perform data analysis.ResultsForty-two tobacco-related stakeholders were identified and classified into eight groups of governmental executives, legislative body, non-governmental organizations, mass media, universities, clerics and imitators, the tobacco industry, and international organizations. The Iranian Parliament and public sector stakeholders have the central role in all stages of the policymaking process. The state actors prevail in all stages of Iran's tobacco control policymaking. The number of non-governmental organizations active in the field of tobacco control was limited. Notably, there exists a conflict of interest between the actors in the two areas of tobacco control and the tobacco industry. Health-related organizations in Iran exhibit a weak coalition for tobacco control, lacking influence over the tobacco industry and smuggling control actors, while various stakeholders have diverse interests impacting their relationships.ConclusionStrengthening the government's tobacco control capacity and developing a national tobacco control strategy, in which intersectoral collaboration between different actors is established, can reduce the conflict of interests between involved actors in Iran. This, in turn, leads to a reduction in the smoking rate and an improvement in public health in Iran.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Tobacco policy (in)coherence in Mozambique: an examination of national and subnational stakeholder perspectives
    Nguenha, Nicole
    Rodriguez, Charo
    Drope, Jeffrey
    Bialous, Stella Aguinaga
    Cunguara, Benedito
    Lencucha, Raphael
    HEALTH POLICY AND PLANNING, 2024, 39 (04) : 333 - 343
  • [22] Exploring policy processes against microbial threats in Iran: a qualitative policy analysis
    Raoofi, Azam
    Takian, Amirhossein
    Akbari Sari, Ali
    Yunesian, Masud
    BMJ OPEN, 2025, 15 (01):
  • [23] Out of pocket or out of control: A qualitative analysis of healthcare professional stakeholder involvement in pharmaceutical policy change in Ireland
    O'Brien, Gary L.
    Sinnott, Sarah-Jo
    O' Flynn, Bridget
    Walshe, Valerie
    Mulcahy, Mark
    Byrne, Stephen
    HEALTH POLICY, 2020, 124 (04) : 411 - 418
  • [24] A Retrospective Analysis of Universal Health Insurance Policy-Making Process in Iran: A Qualitative Study
    Kabir, Mohammad Javad
    Heidari, Alireza
    Lotfi, Mansoureh
    Khatirnamani, Zahra
    Golpira, Reza
    HEALTH SCIENCE REPORTS, 2024, 7 (11)
  • [25] Challenges and opportunities for tobacco control in Australia: a qualitative study
    Jongenelis, Michelle, I
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, 2022, 46 (05) : 689 - 695
  • [26] Why is tobacco control progress in Indonesia stalled? - a qualitative analysis of interviews with tobacco control experts
    Astuti, Putu Ayu Swandewi
    Assunta, Mary
    Freeman, Becky
    BMC PUBLIC HEALTH, 2020, 20 (01)
  • [27] Why is tobacco control progress in Indonesia stalled? - a qualitative analysis of interviews with tobacco control experts
    Putu Ayu Swandewi Astuti
    Mary Assunta
    Becky Freeman
    BMC Public Health, 20
  • [28] Alcohol policy in Iran: Policy content analysis
    Al-Ansari, Basma
    Thow, Anne-Marie
    Mirzaie, Masoud
    Day, Carolyn A.
    Conigrave, Katherine M.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 73 : 185 - 198
  • [29] Assessing the development of health technology assessment in Iran: a policy analysis using Kingdon's Multiple streams framework: a qualitative study
    Behzadifar, Meysam
    Shahabi, Saeed
    Bakhtiari, Ahad
    Azari, Samad
    Ehsanzadeh, Seyed Jafar
    Yarahmadi, Mohammad
    Behzadifar, Masoud
    BMC PUBLIC HEALTH, 2025, 25 (01)
  • [30] Navigating barriers to health technology assessment development in Iran: a qualitative exploration of stakeholder perspectives
    Behzadifar, Meysam
    Shahabi, Saeed
    Bakhtiari, Ahad
    Azari, Samad
    Yarahmadi, Mohammad
    Aryankhesal, Aidin
    Teli, Banafsheh Darvishi
    Behzadifar, Masoud
    ARCHIVES OF PUBLIC HEALTH, 2025, 83 (01)